What is the 13F Pro Quality Score for URGN?

13F Pro ranks UroGen Pharma Ltd. (URGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View URGN's current score at https://13fpro.ai/research/URGN (free sign-up required for the full ranking).

Which hedge funds own the most URGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of URGN include RTW INVESTMENTS,, BlackRock,, TORONTO DOMINION BANK. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/URGN as soon as new 13F filings post.

Where does 13F Pro source URGN data?

All UroGen Pharma Ltd. fundamentals and ownership data come directly from SEC EDGAR. UroGen Pharma Ltd. files with the SEC under CIK 1668243. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is URGN in?

UroGen Pharma Ltd. (URGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is URGN research updated on 13F Pro?

URGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

UroGen Pharma Ltd.(URGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1668243 URGN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

URGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for UroGen Pharma Ltd. (URGN), a Healthcare sector company. URGN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), UroGen Pharma Ltd. reports quarterly revenue of $51.0M, net income of $-23.6M, free cash flow of $-45.4M. Top institutional holders of URGN by reported 13-F value include RTW INVESTMENTS,, BlackRock,, TORONTO DOMINION BANK, based on the most recent SEC filings. URGN trades on the Nasdaq exchange and files with the SEC under CIK 1668243. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate URGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UroGen Pharma Ltd. directly from SEC EDGAR. UroGen Pharma Ltd.'s 13F Pro composite quality score has ranged between 4 and 29 since 2021, currently 26.5 — an improving long-term trajectory across 20 quarterly and live scoring snapshots.

Revenue

Q1 2026

$51.0M

Net Income

Q1 2026

$-23.6M

Free Cash Flow

Q1 2026

$-45.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+21.4% YoY

$109.8MFY 2025

FY22 $64.4MFY23 $82.7MFY24 $90.4MFY25 $109.8M

Net Income

-21.0% YoY

$-153.5MFY 2025

FY22 $-109.8MFY23 $-102.2MFY24 $-126.9MFY25 $-153.5M

Operating Income

-29.0% YoY

$-124.9MFY 2025

FY22 $-79.0MFY23 $-65.5MFY24 $-96.8MFY25 $-124.9M

Total Assets

-29.8% YoY

$200.5MFY 2025

FY22 $135.6MFY23 $178.3MFY24 $285.7MFY25 $200.5M

Total Debt

+2.7% YoY

$125.0MFY 2025

FY22 $97.5MFY23 $98.6MFY24 $121.7MFY25 $125.0M

Op. Cash Flow

-67.9% YoY

$-162.4MFY 2025

FY22 $-87.6MFY23 $-76.4MFY24 $-96.8MFY25 $-162.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$109.8M +21.4%	$90.4M +9.3%	$82.7M +28.5%	$64.4M +34.0%	$48.0M +307.2%	$11.8M
Net Income	$-153.5M -21.0%	$-126.9M -24.1%	$-102.2M +6.9%	$-109.8M +0.9%	$-110.8M +13.7%	$-128.5M
Operating Income	$-124.9M -29.0%	$-96.8M -47.7%	$-65.5M +17.1%	$-79.0M +14.4%	$-92.3M +27.2%	$-126.7M
Total Assets	$200.5M -29.8%	$285.7M +60.2%	$178.3M +31.5%	$135.6M +13.3%	$119.7M -1.9%	$122.0M
Total Debt	$125.0M +2.7%	$121.7M +23.5%	$98.6M +1.0%	$97.5M	$0.00	—
Operating Cash Flow	$-162.4M -67.9%	$-96.8M -26.7%	$-76.4M +12.8%	$-87.6M -3.1%	$-84.9M +19.8%	$-105.9M

AI Insight: URGN Financial Trends

Revenue accelerated 155% from Q1 2025 to Q1 2026 while operating losses narrowed, but equity deteriorated to -$124M amid rising debt.

• Revenue surged from $20M in Q1 2025 to $51M in Q1 2026, with Q4 2025 marking inflection at $38M.

• Operating income improved from -$37M in Q1 2025 to -$20M in Q1 2026 despite volatile quarterly performance.

• Net income losses moderated from -$50M in Q2 2025 to -$24M in Q1 2026.

⚠ Equity collapsed from $30M in Q2 2024 to -$124M in Q1 2026 as losses accumulated.

⚠ Total debt jumped from $122M to $200M between Q4 2025 and Q1 2026.

⚠ Operating cash flow remained deeply negative at -$45M in Q1 2026 despite revenue growth.

AI Insight: URGN Ratio Trends

Operating margins improved dramatically from -182.3% in Q1 2025 to -39.8% in Q1 2026, signaling meaningful progress toward profitability.

• Operating margin improved from -182.3% in Q1 2025 to -39.8% in Q1 2026, a 142.5 percentage point gain.

• Net profit margin strengthened from -121.3% in Q3 2025 to -46.3% in Q1 2026.

• Return on assets improved from -95.7% in Q2 2025 to -37.2% in Q1 2026.

⚠ Company remains deeply unprofitable with negative margins across all quarters despite recent improvement trend.

⚠ ROIC and debt-to-equity data missing for recent quarters, limiting visibility into capital efficiency.

Get alerted when URGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for UroGen Pharma Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of URGN

RTW INVESTMENTS, LP
$81.7M4,543,895 sh
BlackRock, Inc.
$51.2M2,845,567 sh
TORONTO DOMINION BANK
$47.0M2,616,714 sh
MORGAN STANLEY
$46.0M2,560,038 sh
Kynam Capital Management, LP
$40.4M2,247,393 sh
LEUCADIA NATIONAL CORP
$39.5M2,199,652 sh
Paradigm Biocapital Advisors LP
$30.6M1,703,949 sh
ACORN CAPITAL ADVISORS, LLC
$30.1M1,673,420 sh
AMERICAN CENTURY COMPANIES INC
$29.4M1,637,570 sh
SILVERARC CAPITAL MANAGEMENT, LLC
$27.0M1,503,045 sh

Fund	Value	Shares
RTW INVESTMENTS, LP	$81.7M	4,543,895
BlackRock, Inc.	$51.2M	2,845,567
TORONTO DOMINION BANK	$47.0M	2,616,714
MORGAN STANLEY	$46.0M	2,560,038
Kynam Capital Management, LP	$40.4M	2,247,393
LEUCADIA NATIONAL CORP	$39.5M	2,199,652
Paradigm Biocapital Advisors LP	$30.6M	1,703,949
ACORN CAPITAL ADVISORS, LLC	$30.1M	1,673,420
AMERICAN CENTURY COMPANIES INC	$29.4M	1,637,570
SILVERARC CAPITAL MANAGEMENT, LLC	$27.0M	1,503,045

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put URGN on your watchlist

Track score changes the day UroGen Pharma Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is URGN a good stock to buy?

13F Pro's AI-powered analysis of UroGen Pharma Ltd. (URGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for URGN are available on the URGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own URGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling URGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of UroGen Pharma Ltd.'s investment landscape.